ZDHHC11 Knockout cell line (PC9-OR1)
Red cotton OmniCell bank
Online inquireOverview
Ubigene gene knockout cell lines mediated by optimized CRISPR-Cas9 technology provide reliable in vitro models for investigating gene function, signaling pathways, disease mechanisms, and therapeutic targets.
Osimertinib resistance characterizes PC9-OR1, a human lung adenocarcinoma cell line derived from the PC-9 parental line and selected for resistance to osimertinib. The cells originated from a metastatic lymph node of a 45-year-old male and retain the EGFR exon 19 deletion and TP53 mutation documented in the parental line. PC9-OR1 is classified as a human lung adenocarcinoma cell line.
Comprehensive quality control includes STR authentication, sterility testing (bacteria and fungi), and mycoplasma screening to ensure purity and performance. Genotype is confirmed by two rounds of PCR and Sanger sequencing, and complete validation reports are provided for make-to-order products.
Product Overview
Key Advantages
Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations
These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.
Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.
Quality Control Specifications
Knockout Region: E1
Reference Transcript: ZDHHC11-201
Validation Method: PCR amplification+Sanger sequencing
Intended use
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use
Unpacking and Storage Instructions
Handling procedure
References
FAQ
Related Popular Products
Contact Us
Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours
* Name
* Institution
* Products & Services of Interest
If email is not available, how else can we reach you?
How did you hear about us?
